Daniel Weng

Vice President Finance | Shanghai, China

Professional Overview

Daniel Weng is an accomplished finance executive with over 15 years of experience in the pharmaceutical and chemical industries. As the Vice President of Finance at Transcenta Group, he oversees the company's financial operations, strategic planning, and business performance optimization across global markets.

Experience Summary

Current Role

As the Vice President of Finance at Transcenta Group since December 2021, Daniel is responsible for leading the company's financial strategy, reporting, and risk management initiatives. He plays a crucial role in supporting the organization's growth and expansion plans, ensuring financial resilience and operational efficiency.

Career Progression

Prior to his current role, Daniel served as the Vice President and Head of Finance at CStone Pharmaceuticals, where he spearheaded the implementation of robust financial controls and data-driven decision-making processes. He has also held senior finance positions at Everest Medicines and Amgen China, where he was instrumental in driving financial performance and aligning operations with strategic objectives.

Earlier in his career, Daniel served as the Asia Pacific Finance Controller A&AC at AkzoNobel, where he leveraged his expertise in financial reporting, treasury management, and cross-functional collaboration to enhance the company's regional financial operations.

Academic Background

Daniel holds a Master's degree in Business Administration from the China Europe International Business School (CEIBS), where he specialized in Finance. He also earned a Bachelor's degree in Economics from Fudan University, a prestigious institution in China.

Areas of Expertise

• Financial planning and analysis

• Treasury management and cash flow optimization

• Strategic business partnering and cross-functional collaboration

• Risk management and internal controls

• Financial reporting and regulatory compliance

• Mergers, acquisitions, and integration

Professional Impact

Throughout his career, Daniel has demonstrated a track record of driving financial excellence and operational improvements. At Amgen China, he played a pivotal role in enhancing the company's financial reporting capabilities, leading to improved transparency and informed decision-making. At CStone Pharmaceuticals, he spearheaded the implementation of a robust financial control framework, which contributed to the company's successful IPO and capital raising initiatives.

Conclusion

With his extensive experience, strategic mindset, and strong technical expertise, Daniel Weng is a valuable asset to Transcenta Group. He is committed to leveraging his finance acumen to support the company's growth, optimize its financial performance, and contribute to the overall success of the organization.